NCT04097600View on ClinicalTrials.gov

A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

274

Participants

Timeline

Start Date

September 30, 2019

Primary Completion Date

December 16, 2020

Study Completion Date

January 20, 2021

Conditions
Healthy VolunteersType 2 Diabetes
Interventions
DRUG

Oral semaglutide

Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks

Trial Locations (1)

14050

Novo Nordisk Investigational Site, Berlin

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY